The Readout Loud
291: The plight of the VC, Gilead's latest setback, & more M&A
This episode isn’t summarized yet
Create a free account and summarize it. In a few minutes you’ll have the key takeaways and a section-by-section summary.
Show notes
We discuss how biotech's downturn has made life difficult not just for startups but also the VCs they rely on for much-needed funding. We also take a look at Gilead Sciences' struggle to turn itself into an oncology company and the latest biotech to get bought out by a major pharma firm.
Subscribe to our biotech newsletter, The Readout.